English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Lilly Hopes China Business Continues to Flourish with New Corporate Initiatives

Dec. 9, 2009

Eli Lilly's China revenue in 2008 was an estimated USD 200 million - but 2009 revenues are expected to see a growth of up to 20%. The company has been increasing its presence in China and is currently building an insulin manufacturing plant in Suzhou, its second facility in the area.
According to a company press release, Lilly plans to undertake three initiatives to boost its business in China, including accelerating product launches, adding non-Lilly products through acquisitions or co-marketing deals, and establishing local alliances.